Navigation Links
JCI early table of contents for May 1, 2013
Date:5/1/2013

HPV leaves its mark in oropharyngeal squamous cell carcinomas

Oropharyngeal squamous cell carcinoma (OPSCC) is a form of cancer that affects the cells lining the middle part of the throat, including the soft palate, the base of the tongue, the tonsils, and the pharynx. High-risk types of human papilloma virus (HPV) are increasingly detected in patients with OPSCC; however, HPV-positive OPSCC is highly curable and patients with HPV have better survival compared to HPV-negative patients, whose cancers are usually associate with alcohol and tobacco use. To understand the molecular mechanisms underlying these differences, Jochen Hess and colleagues at University Hospital Heidelberg in Heidelberg, Germany monitored changes in DNA modifications in HPV-positive and HPV-negative OPSCCs. In this issue of the Journal of Clinical Investigation, they identified a specific pattern of DNA modifications that is dependent on the presence of HPV. This DNA modification pattern was significantly correlated with improved survival in three separate groups of OPSCC patients. This study identifies a specific cellular alteration that can predict clinical outcomes for patients with OPSCC.

TITLE:
HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas

AUTHOR CONTACT:
Jochen Hess
University Hospital Heidelberg, Heidelberg, DEU
Phone: +49 (0)6221 56 39505; E-mail: jochen.hess@med.uni-heidelberg.de

View this article at: http://www.jci.org/articles/view/67010?key=e49a18f8713a54db36d3


Searching for therapeutic synergy in primary effusion lymphoma

Primary effusion lymphoma (PEL) is a rare, fatal form of aggressive B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). The disease most commonly occurs in immunocompromised patients, such as those with HIV and the elderly. Because current treatment options are not effective, there is a great need for new PEL therapies. In this issue of the Journal of Clinical Investigation, Juan Carlos Ramos and colleagues at the University of Miami used an immunocompromised mouse model of PEL to determine the efficacy of Bortezomib/Vorinostat combination therapy, two drugs that are currently being used to treat multiple myeloma and cutaneous T cell lymphoma, respectively. They found that this treatment combination reactivated virus-induced cell lysis and induced PEL cell death, increasing the lifespan of mice with PEL tumors. These findings indicate that this drug combination could potentially be beneficial in immunocompromised patients with KSHV-associated malignancies.

TITLE:
Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma

AUTHOR CONTACT:
Juan Carlos Ramos
Leonard M. Miller School of Medicine, University of Miami, Miamia, FL, USA
Phone: 305-243-6611; Fax: 305-243-5239; E-mail: jramos2@med.miami.edu

View this article at: http://www.jci.org/articles/view/64503?key=911b173313cf3a75e17c


ALSO IN THIS ISSUE

TITLE:
Plasmacytoid dendritic cells promote rotavirus-induced human and murine B-cell responses

AUTHOR CONTACT:
Harry B Greenberg
Stanford University School of Medicine, Stanford, CA, USA
Phone: 650 725 9722; E-mail: harry.greenberg@stanford.edu

View this article at: http://www.jci.org/articles/view/60945?key=92da3ab7cb1e7d28deb4

TITLE:
Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth

AUTHOR CONTACT:
Pilar Snchez-Gmez
Instituto de Salud Carlos III-UFIEC, Majadahonda, UNK, ESP
Phone: 34918223265; Fax: 34918223269; E-mail: psanchezg@isciii.es

View this article at: http://www.jci.org/articles/view/63623?key=a0b7cd2c477b6bade3de

TITLE:
PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice

AUTHOR CONTACT:
Zhiwei Chen
AIDS Institute, Hong Kong, HKG
Phone: 85228199831; Fax: 85228199824; E-mail: zchenai@hku.hk

View this article at: http://www.jci.org/articles/view/64704?key=17828494be1b33866ebd

TITLE:
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer

AUTHOR CONTACT:
So Young Kim
Duke University, Durham, NC, USA
Phone: 919-684-7955; E-mail: soyoung.kim@duke.edu

View this article at: http://www.jci.org/articles/view/66343?key=13fcaece6930940c5e5a

TITLE:
Fetal-derived adrenomedullin mediates the innate immune milieu of the placenta

AUTHOR CONTACT:
Kathleen M. Caron
The Univ. of North Carolina-Chapel Hill, Chapel Hill, NC, USA
Phone: (919) 966-5215; Fax: (919) 966-5230; E-mail: kathleen_caron@med.unc.edu

View this article at: http://www.jci.org/articles/view/67039?key=3afdba3bdd597a169a37

TITLE:
Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance

AUTHOR CONTACT:
Amer Beg
LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, Tampa, FL, USA
Phone: 813-745-5714; E-mail: amer.beg@moffitt.org

View this article at: http://www.jci.org/articles/view/67250?key=ec2f042511c98c04245d


'/>"/>

Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Related medicine news :

1. New Stool Test Might Aid in Early Detection of Colon Cancer
2. An Early Start for Your Child with Autism
3. Early Study Finds Some Promise for Lung Cancer Vaccine
4. Treat Rheumatoid Arthritis Early and Aggressively: Guidelines
5. JCI early table of contents for April 9, 2012
6. Eye Tremors May Aid Early Diagnosis of Parkinsons: Study
7. Nearly 1 in 4 grandparents store prescription medicines where children can easily find them
8. First contact: Early intervention key in diagnosis and treatment of serious mental illness
9. Brain Tumor Vaccine Shows Promise in Early Trial
10. Role of Screening, Monitoring in Early Kidney Disease Unclear
11. Detecting malaria early to save lives: New optical technique promises rapid and accurate diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology: